Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

REVCO CHRISTMAS SALES INCREASED 23% ON LIKE-STORE BASIS, putting the chain "in the high end of the range of Christmas gains reported by the nation's largest retailers and well above results for the chain drugstore industry as a whole," Revco Chairman Sidney Dworkin reported. The strong five-week period at the end of the year was a shot in the arm for Revco; for the 36-week period ended Feb. 4, like-store sales are up at the slower 13.5% rate (including the Christmas boost). Total sales for the first three quarters of the fiscal year reached $1.4 bil. compared to $1.2 bil. in 1983. "Pharmacy sales, which account for approximately 30% of Revco's store sales, rose 11.3% on a like-store basis for the (third) quarter," the company reported. For the nine months, they were up 12.8%. The company maintained that the pharmacy gains were "achieved without a high incidence of influenza, a factor which contributed significantly to sales gains a year ago." The chain says it is on-target to reach 120 net openings in 1984: the firm had added 87 stores through the first nine months. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts